Co-Expression of miR155 or LSD1 shRNA Increases the Anti-Tumor Functions of CD19 CAR-T Cells

Chimeric antigen receptor (CAR) T cells targeting CD19 antigen have produced remarkable clinical outcomes for cancer patients. However, identifying measures to enhance effector function remains one of the most challenging issues in CD19-targeted immunotherapy. Here, we report a novel approach in whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jing, Zhu, Jingjing, Zheng, Genhui, Wang, Qianyu, Li, Xiaorui, Feng, Yaru, Shang, Fengqin, He, Siqi, Jiang, Qiyao, Shi, Bingjie, Wang, Dong, Cao, Zhiwei, Wang, Jianxun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761951/
https://www.ncbi.nlm.nih.gov/pubmed/35046962
http://dx.doi.org/10.3389/fimmu.2021.811364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761951/
https://www.ncbi.nlm.nih.gov/pubmed/35046962
http://dx.doi.org/10.3389/fimmu.2021.811364

Ejemplares similares